General
Preferred name
PARICALCITOL
Synonyms
Paricalcitol-D6 ()
Zemplar ()
COMPOUND-49510 ()
Compound 49510 ()
P&D ID
PD009651
CAS
131918-61-1
Tags
available
drug
Approved by
FDA
First approval
1998
Drug indication
Chronic kidney disease
Hyperparathyroidism
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Vitamin D receptor agonist
(GtoPdb)
PRICE
766
DESCRIPTION
Paricalcitol is a vitamin D receptor agonist. It is used for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
DESCRIPTION
Paricalcitol is a vitamin D analog used to treat hyperparathyroidism associated with stage 3 or greater chronic kidney disease.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
19
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NURSA ligand set
Other bioactive compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
140
Molecular Weight
416.33
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
0
cLogP
5.56
TPSA
60.69
Fraction CSP3
0.78
Chiral centers
7.0
Largest ring
6.0
QED
0.51
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
VD/VDR
VDR
Pathway
Vitamin D Related
Vitamin D Related/Nuclear Receptor
Member status
member
MOA
Cytochrome P450c24 (CYP24) Inhibitors
Cytochrome P450 CYP3A4 Inhibitors
Parathyroid Hormone Secretion Inhibitors
Signal Transduction Modulators
Vitamin D Receptor (VDR) Agonists
vitamin D receptor agonist
Indication
chronic kidney disease (CKD), hyperthyroidism
Disease Area
nephrology, endocrinology
Biosynthetic Origin
Terpenoid
Therapeutic Indication
Calcium Metabolism
Therapeutic Class
Hormone Therapy
Parasympathomimetics
Source data

